NASDAQ:TPST Tempest Therapeutics (TPST) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free TPST Stock Alerts $3.39 -0.05 (-1.45%) (As of 02:45 PM ET) Add Compare Share Share Today's Range$3.31▼$3.4450-Day Range$3.10▼$5.4452-Week Range$0.17▼$9.77Volume205,192 shsAverage Volume945,430 shsMarket Capitalization$75.22 millionP/E RatioN/ADividend YieldN/APrice Target$22.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Tempest Therapeutics alerts: Email Address Tempest Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside552.5% Upside$22.25 Price TargetShort InterestBearish6.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.58) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 starsMedical Sector847th out of 907 stocksPharmaceutical Preparations Industry397th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingTempest Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTempest Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.74% of the float of Tempest Therapeutics has been sold short.Short Interest Ratio / Days to CoverTempest Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tempest Therapeutics has recently increased by 16.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTempest Therapeutics does not currently pay a dividend.Dividend GrowthTempest Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TPST. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 18 people have searched for TPST on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows19 people have added Tempest Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 171% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.80% of the stock of Tempest Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.52% of the stock of Tempest Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tempest Therapeutics are expected to decrease in the coming year, from ($1.58) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tempest Therapeutics is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tempest Therapeutics is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTempest Therapeutics has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Tempest Therapeutics Stock (NASDAQ:TPST)Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.Read More TPST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TPST Stock News HeadlinesApril 15, 2024 | americanbankingnews.comTempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Up 26.5% in MarchApril 9, 2024 | markets.businessinsider.comBuy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug DevelopmentsApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 9, 2024 | finance.yahoo.comTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual MeetingApril 9, 2024 | globenewswire.comTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual MeetingApril 6, 2024 | uk.investing.comTempest Therapeutics moves TPST-1120 into phase 3 trialApril 4, 2024 | finance.yahoo.comTempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research CommunicationsApril 4, 2024 | globenewswire.comTempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research CommunicationsApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 21, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)March 20, 2024 | finanznachrichten.deTempest Therapeutics: Tempest Reports Year End 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | investorplace.comTPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023March 19, 2024 | finance.yahoo.comTempest Reports Year End 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | globenewswire.comTempest Reports Year End 2023 Financial Results and Provides Business UpdateMarch 14, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)March 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tempest Therapeutics Amid Strong TPST-1120 Preclinical and Financial ProspectsMarch 12, 2024 | finance.yahoo.comTempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer TypesMarch 5, 2024 | globenewswire.comTempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual MeetingFebruary 26, 2024 | finance.yahoo.comTempest to Present at the 44th Annual TD Cowen Healthcare ConferenceJanuary 30, 2024 | finance.yahoo.comTempest Therapeutics, Inc. (TPST)December 28, 2023 | benzinga.comTempest Therapeutics Stock (NASDAQ:TPST), Short Interest ReportDecember 11, 2023 | benzinga.comTempest Therapeutics Stock (NASDAQ:TPST) Insider TradesDecember 2, 2023 | finanznachrichten.deTempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 1, 2023 | finance.yahoo.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 20, 2023 | finance.yahoo.comTempest to Present at the 35th Annual Piper Sandler Healthcare ConferenceNovember 11, 2023 | markets.businessinsider.comGrowth Potential and Strategic Partnerships: Reasons for Aydin Huseynov’s Buy Rating on Tempest TherapeuticsNovember 11, 2023 | msn.comTempest Therapeutics (NASDAQ:TPST) Blasts Up on Improved Cash PictureSee More Headlines Receive TPST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today4/25/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TPST CUSIPN/A CIK1544227 Webwww.millendo.com Phone415-798-8589FaxN/AEmployees17Year Founded2012Price Target and Rating Average Stock Price Target$22.25 High Stock Price Target$47.00 Low Stock Price Target$13.00 Potential Upside/Downside+552.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-283.87% Return on Assets-82.11% Debt Debt-to-Equity Ratio0.23 Current Ratio4.29 Quick Ratio4.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.39 per share Price / Book2.45Miscellaneous Outstanding Shares22,190,000Free Float20,905,000Market Cap$75.67 million OptionableOptionable Beta-1.76 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Stephen R. Brady J.D. (Age 54)LLM, CEO, President & Director Comp: $740.95kDr. Samuel Whiting M.D. (Age 58)Ph.D., Executive VP & Chief Medical Officer Comp: $591.23kMr. Nicholas Maestas (Age 44)VP of Strategy & Finance and Secretary Mr. Justin Trojanowski (Age 36)Corporate Controller, Treasurer & Principal Accounting Officer Ms. Lindsay YoungHead of Human ResourcesDr. Sharon Sakai Ph.D.RAC, Head of Regulatory & QualityMore ExecutivesKey CompetitorsHookipa PharmaNASDAQ:HOOKYS BiopharmaNASDAQ:YSConnect BiopharmaNASDAQ:CNTBCorvus PharmaceuticalsNASDAQ:CRVSSpero TherapeuticsNASDAQ:SPROView All CompetitorsInstitutional OwnershipMayTech Global Investments LLCBought 10,000 shares on 2/15/2024Ownership: 0.052%Simplex Trading LLCBought 18,000 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions TPST Stock Analysis - Frequently Asked Questions Should I buy or sell Tempest Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tempest Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TPST shares. View TPST analyst ratings or view top-rated stocks. What is Tempest Therapeutics' stock price target for 2024? 4 brokers have issued twelve-month target prices for Tempest Therapeutics' shares. Their TPST share price targets range from $13.00 to $47.00. On average, they predict the company's stock price to reach $22.25 in the next twelve months. This suggests a possible upside of 552.5% from the stock's current price. View analysts price targets for TPST or view top-rated stocks among Wall Street analysts. How have TPST shares performed in 2024? Tempest Therapeutics' stock was trading at $4.40 at the start of the year. Since then, TPST stock has decreased by 22.5% and is now trading at $3.41. View the best growth stocks for 2024 here. Are investors shorting Tempest Therapeutics? Tempest Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 969,700 shares, an increase of 26.5% from the March 15th total of 766,800 shares. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is presently 0.9 days. Approximately 6.1% of the company's shares are sold short. View Tempest Therapeutics' Short Interest. When is Tempest Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TPST earnings forecast. How were Tempest Therapeutics' earnings last quarter? Tempest Therapeutics, Inc. (NASDAQ:TPST) announced its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. When did Tempest Therapeutics' stock split? Tempest Therapeutics shares reverse split on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Tempest Therapeutics? Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TPST) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
